• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 1, 2019

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Many hair follicles that stop producing hairs contain quiescent stem cells, suggesting that waking up those cells could reverse hair loss. Researchers at Columbia University have discovered that the hair follicle stem cells are actively restrained by tissue macrophages.  Read More

Regulatory actions for March 29, 2019

Read More

Clinical data for March 29, 2019

Read More

Financings

Micreos BV, of Hague, the Netherlands, said it secured €30 million (US$33.6 million) in funding to accelerate the development of its endolysin technology. The proceeds will support the clinical development program of its endolysin XZ-700 and the U.S. launch of its OTC Gladskin product for eczema. Read More

Other news to note

Boehringer Ingelheim GmbH, of Ingelheim, Germany, acquired ICD Therapeutics GmbH, of Berlin. The acquisition includes rights to ICD's Macrodel biologics delivery platform. Boehringer will employ that platform for the development of therapeutics in collaboration with Nanopet Pharma GmbH, of Berlin, a former shareholder of ICD. Further details of the acquisition were not disclosed. Read More

Changes to clinical trials rules to accelerate drug access in India

HYDERABAD, India – India has modified its rules to allow the government to waive clinical trials for some new drugs that are approved and marketed in countries specified by India's apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO). Read More

Glioblastoma-on-a-chip predicts therapeutic responses

Korean bioengineers and neurosurgeons have developed a novel patient-specific bioprinted tumor-on-a-chip model of glioblastoma, which might prove useful for identifying optimal treatments for patients resistant to standard first-line therapies. Read More

Ebola cases in DRC top 1K as ring vaccination strategy, therapeutic efforts continue

LONDON – Its geographical spread is said to be contained, but the number of cases of Ebola in the Democratic Republic of Congo (DRC) has now passed 1,000, and the latest update shows a rise in new cases last week. Read More

Investors remain cautious as sector underperforms the general markets

It was a tough month for biopharmaceutical companies as a combination of clinical trial failures and drug pricing rhetoric ramping up in Washington kept investors sitting on their hands. As a result, the BioWorld Biopharmaceutical Index fell more than 6 percent in value, underperforming the general markets, with the Dow Jones Industrial Average closing March just below water and the Nasdaq Composite index recording an almost 2 percent gain in the same period.  Read More

The uncaged Finch sings for Gilead and Galapagos as filgotinib soars in phase III

Gilead Sciences Inc. and Galapagos NV announced week 24 results for phase III studies Finch 1 and 3 of filgotinib in rheumatoid arthritis (RA), saying both studies reached their primary endpoints and that Finch 1 hit key secondary endpoints. Read More

Bluebird Bio gets European nod for lentiglobin in beta-thalassemia

DUBLIN – The March meeting of the EMA's Committee for Human Medicinal Products (CHMP), the first to be held in its new home in Amsterdam, must have been a rather quiet affair. Just one new therapy was up for consideration – Bluebird Bio Inc.'s lentiglobin cell and gene therapy for beta-thalassemia – and it duly came out with a positive vote, which paves the way for a formal European Commission approval in the second quarter. The treatment, which comprises autologous CD34 cells transduced with a lentiviral vector, lentiglobin 3305, expressing a working copy of the beta-globin gene, will be marketed as Zynteglo. Read More

Astrazeneca to pay up to $6.9B for Daiichi-developed cancer ADC

Astrazeneca plc, faced with what CEO Pascal Soriot recently called "probably the largest patent expiry in the industry as a proportion of the total company," has agreed to pay Daiichi Sankyo Co. Ltd. up to $6.9 billion to jointly develop and commercialize an antibody-drug conjugate (ADC) for the potential treatment of multiple HER2-expressing cancers. The deal for trastuzumab deruxtecan (DS-8201), which could have big benefits for both companies, includes $1.35 billion up front for Daiichi Sankyo. It could also yield a further $5.55 billion in milestone payments to the Tokyo-based big pharma. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe